Latest H5N1 clinical trials Stories
For the first time, a malaria vaccine that uses the entire malaria parasite has proven safe and shown promise to produce a strong immune response in a clinical trial.
Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy.
New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection.
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- GeoVax Labs, Inc.
SAN DIEGO, Aug.
QUEBEC CITY, QC, Aug. 12, 2011 /PRNewswire/ - Medicago Inc.
BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).
NESS ZIONA, Israel, June 16, 2011 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) [http://www.biondvax.com ] today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
- To swell, as grain or wood with water.